Fabior

Warnings
Precautions

WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

Fetal Risk

Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in orally treated animals. Tazarotene is a teratogenic substance, and it is not known what level of exposure is required for teratogenicity in humans [see CLINICAL PHARMACOLOGY].

There were five reported pregnancies in patients who participated in clinical trials for topical tazarotene foam. One of the patients was found to have been treated with topical tazarotene for 25 days, two were treated with vehicle foam and the other two did not receive either tazarotene foam or vehicle foam. The patients were discontinued from the trials when their pregnancy was reported. The one pregnant woman who was inadvertently exposed to topical tazarotene during the clinical trial delivered a full-term healthy infant.

Females of Childbearing Potential

Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when tazarotene Foam is used. The possibility of pregnancy should be considered in females of child-bearing potential at the time of institution of therapy.

A negative serum or urine result for pregnancy test having a sensitivity down to at least 25 mIU/mL for human chorionic gonadotropin (hCG) should be obtained within 2 weeks prior to Fabior Foam therapy, which should begin during a normal menstrual period, for females of childbearing potential. Advise patients of the need to use an effective method of contraception to avoid pregnancy [see Use In Specific Populations].

Local Irritation

Fabior Foam should be used with caution in patients with a history of local tolerability reactions or local hypersensitivity. Retinoids should not be used on abraded or eczematous skin, as they may cause severe irritation. Contact with the mouth, eyes, and mucous membranes should be avoided. In case of accidental contact, rinse well with water.

Some individuals may experience skin redness, peeling, burning or excessive pruritus. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the dosing should be reduced to an interval the patient can tolerate. However, efficacy at reduced frequency of application has not been established.

Weather extremes, such as wind or cold, may be more irritating to patients using Fabior Foam.

Potential Irritant Effect with Concomitant Topical Medications

Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.

Photosensitivity and Risk for Sunburn

Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided. Patients must be warned to use sunscreens and protective clothing when using Fabior Foam. Patients with sunburn should be advised not to use Fabior Foam until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using Fabior Foam and ensure that the precautions are observed [see FDA-approved patient labeling]. Due to the potential for photosensitivity resulting in greater risk for sunburn, Fabior Foam should be used with caution in patients with a personal or family history of skin cancer.

Fabior Foam should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

Flammability

The propellant in Fabior Foam is flammable. Instruct the patient to avoid fire, flame, and/or smoking during and immediately following application.

Patient Counseling Information

“See FDA-approved patient labeling (PATIENT INFORMATION)

Inform the patient of the following:

  • Fetal risk associated with Fabior Foam for females of childbearing potential. Advise patients to use an effective method of contraception during treatment to avoid pregnancy. Advise the patient to stop medication if she becomes pregnant and call her doctor.
  • If undue irritation (redness, peeling, or discomfort) occurs, reduce frequency of application or temporarily interrupt treatment. Treatment may be resumed once irritation subsides.
  • Do not place Fabior Foam in the freezer.
  • Avoid exposure of the treated areas to either natural or artificial sunlight, including tanning beds and sun lamps.
  • Avoid contact with the eyes. If Fabior Foam gets in or near their eyes, to rinse thoroughly with water.
  • Wash their hands after applying Fabior Foam.
  • Avoid fire, flame, or smoking during and immediately following application since Fabior Foam is flammable.
  • Keep out of the reach of children.
  • Not for ophthalmic, oral, or intravaginal use.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

A long-term study of tazarotene following oral administration of 0.025, 0.050, and 0.125 mg/kg/day to rats showed no indications of increased carcinogenic risk. Based on pharmacokinetic data from a shorter-term study in rats, the highest dose of 0.125 mg/kg/day was anticipated to give systemic exposure in rats approximately 2 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

A long-term topical application study of up to 0.1% tazarotene in a gel formulation in mice terminated at 88 weeks showed that dose levels of 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced to 0.5 mg/kg/day for males after 41 weeks due to severe dermal irritation) revealed no apparent carcinogenic effects when compared to vehicle control animals. Systemic exposure (AUC) at the highest dose in mice was 49 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

In evaluation of photo-carcinogenicity, median time to onset of tumors was decreased, and the number of tumors increased in hairless mice following chronic topical dosing with exposure to ultraviolet radiation at tazarotene concentrations of 0.001%, 0.005%, and 0.01% in a gel formulation for up to 40 weeks.

Mutagenesis

Tazarotene was non-mutagenic in the Ames assay and did not produce structural chromosomal aberrations in a human lymphocyte assay. Tazarotene was non-mutagenic in the CHO/HGPRT mammalian cell forward gene mutation assay and was non-clastogenic in the in vivo mouse micronucleus test.

Impairment of Fertility

No impairment of fertility was observed in rats when male animals were treated for 70 days prior to mating and female animals were treated for 14 days prior to mating and continuing through gestation and lactation with topical doses of tazarotene gel up to 0.125 mg/kg/day. Based on data from another study, the systemic drug exposure at the 0.125 mg/kg/day dose in rats would be equivalent to 7.6 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

No impairment of mating performance or fertility was observed in male rats treated for 70 days prior to mating with oral doses of up to 1 mg/kg/day tazarotene. Systemic exposure (AUC) at the highest dose in rats was 23 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

No effect on parameters of mating performance or fertility was observed in female rats treated for 15 days prior to mating and continuing through gestation day 7 with oral doses of tazarotene up to 2 mg/kg/day. However, there was a significant decrease in the number of estrous stages and an increase in developmental effects at that dose [see Pregnancy ]. Systemic exposure (AUC) at the highest dose in rats was 42 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

Reproductive capabilities of F1 animals, including F2 survival and development, were not affected by topical administration of tazarotene gel to female F0 parental rats from gestation day 16 through lactation day 20 at the maximum tolerated dose of 0.125 mg/kg/day. Based on data from another study, the systemic drug exposure (AUC) in rats would be equivalent to 7.6 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

Use In Specific Populations

Pregnancy

Pregnancy Category X

Fabior Foam is contraindicated in pregnancy [see CONTRAINDICATIONS].

There are no adequate and well-controlled studies with Fabior Foam in pregnant women. Fabior Foam is contraindicated in females who are or may become pregnant [see CONTRAINDICATIONS]. Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when Fabior Foam is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative serum or urine result for pregnancy test having a sensitivity down to at least 25 mIU/mL for hCG should be obtained within 2 weeks prior to Fabior Foam therapy, which should begin during a normal menstrual period, for females of childbearing potential.

In rats, tazarotene 0.05% gel administered topically during gestation days 6 through 17 at 0.25 mg/kg/day resulted in reduced fetal body weights and reduced skeletal ossification. Rabbits dosed topically with 0.25 mg/kg/day tazarotene gel during gestation days 6 through 18 were noted with single incidences of known retinoid malformations, including spina bifida, hydrocephaly, and heart anomalies.

Systemic exposure (AUC) to tazarotenic acid at topical doses of 0.25 mg/kg/day tazarotene in a gel formulation in rats and rabbits were 15 and 166 times, respectively, the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

As with other retinoids, when tazarotene was administered orally to experimental animals, developmental delays were seen in rats, and teratogenic effects and post-implantation loss were observed in rats and rabbits at doses 13 and 325 times, respectively, the systemic exposure (AUC) to tazarotenic acid in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

In female rats orally administered 2 mg/kg/day tazarotene from 15 days before mating through gestation day 7, a number of classic developmental effects of retinoids were observed including decreased number of implantation sites, decreased litter size, decreased numbers of live fetuses, and decreased fetal body weights. A low incidence of retinoid-related malformations was also observed. Systemic exposure (AUC) in rats was 42 times the systemic exposure (AUC) in acne patients treated with 2 mg/cm² of Fabior Foam 0.1% over a 15% body surface area.

Nursing Mothers

After single topical doses of 14C-tazarotene to the skin of lactating rats, radioactivity was detected in milk, suggesting that there would be transfer of drug-related material to the offspring via milk. It is not known whether this drug is excreted in human milk. The safe use of Fabior Foam during lactation has not been established. A decision should be made whether to discontinue breast-feeding or to discontinue Fabior Foam therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Pediatric Use

The safety and effectiveness of Fabior Foam in pediatric patients under 12 years of age have not been established. Clinical studies of Fabior Foam included 860 patients 12 to 17 years of age with acne vulgaris.

Geriatric Use

Fabior Foam for the treatment of acne has not been clinically evaluated in persons over the age of 65.

Last reviewed on RxList: 5/24/2012
This monograph has been modified to include the generic and brand name in many instances.

Warnings
Precautions
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD